SEC Form 4 · accession 0000884731-16-000023
ARIAD PHARMACEUTICALS INC · ARIA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel M Bollag
Officer — Sr. VP, Reg. Affairs & Quality
Period of report
Mar 19, 2016
Accepted (ET)
Mar 22, 2016 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000884731
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 19, 2016 | M | 8,000 | $0.00 | A | 159,088 | D | |
| Common StockF3 | Mar 21, 2016 | S | 4,000 | $6.4677 | D | 155,088 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4,F5 | — | Mar 19, 2016 | M | 8,000 | D | — | — | Common Stock | 8,000 | 0 | D |
Explanation of responses
- F1Shares were acquired upon the vesting of a Restricted Stock Unit dated 03/19/2013
- F2Represents shares sold to satisfy withholding tax requirements pursuant to a Rule 10b5-1 trading plan.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.27 to $6.55, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer,or the staff of the Security and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
- F4Each restricted stock unit represents a right to receive one share of ARIAD common stock.
- F5Restricted Stock Units vest as to 33-1/3% of the award on each of March 19, 2014, March 19, 2015 and March 19, 2016